CNS Pharmaceuticals Inc. Featured in Syndicated Broadcast Covering Activation of First Clinical Trial Sites in Europe Evaluating Berubicin for the Treatment of GBM
07 oct. 2022 08h00 HE
|
CNS Pharmaceuticals, Inc.
LOS ANGELES, Oct. 07, 2022 (GLOBE NEWSWIRE) -- InvestorWire -- CNS Pharmaceuticals Inc. (NASDAQ: CNSP), a clinical stage biotechnology company specializing in the development of novel treatments for...
Glioblastoma Multiforme Treatment Market is expected to register an Excellent CAGR of 8.1%, Upcoming Trends, Revenue, Size, Share, Growth, and Prominent Players By 2029
07 sept. 2022 11h00 HE
|
Data Bridge Market Research
WASHINGTON, DC, Sept. 07, 2022 (GLOBE NEWSWIRE) -- The comprehensive industry research on “Global Glioblastoma Multiforme Treatment Market” published by Data Bridge Market includes growth analysis,...
Brain Cancer Diagnostics Market Revenue to Cross $7.37 Bn Globally, by 2028 at 28.5.% CAGR - Exclusive Report by The Insight Partners
15 juil. 2022 08h30 HE
|
The Insight Partners
New York, July 15, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Brain Cancer Diagnostic Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by...
Telix Collaborates with Olivia Newton-John Cancer Research Institute on Brain Cancer Imaging Study
21 déc. 2021 19h49 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into a clinical data access agreement with...
IPAX-1 Late Breaking Oral Presentation at the Congress of Neurological Surgeons (CNS) Meeting
19 oct. 2021 18h12 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and INDIANAPOLIS, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to announce the first set of peer-reviewed results...
InvestorBrandNetwork Announces C3 Chat Show Podcast with CNS Pharmaceuticals Inc. Chairman and CEO John Climaco
13 janv. 2021 08h30 HE
|
InvestorBrandNetwork (IBN)
LOS ANGELES, Jan. 13, 2021 (GLOBE NEWSWIRE) -- via InvestorWire — InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities, today announces...
Glioblastoma Multiforme Pipeline Expected to Offer Myriad of Novel Therapies in the Next Decade
17 déc. 2020 11h00 HE
|
DelveInsight Business Research LLP
Los Angeles, USA, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Glioblastoma Multiforme Pipeline Expected to Offer Myriad of Novel Therapies in the Next Decade Glioblastoma Multiforme Clinical Trial Analysis...
InvestorBrandNetwork Announces ‘Want Money Got Money’ Podcast with CNS Pharmaceuticals Inc. Chairman and CEO John Climaco
16 déc. 2020 08h30 HE
|
InvestorBrandNetwork (IBN)
LOS ANGELES, Dec. 16, 2020 (GLOBE NEWSWIRE) -- via InvestorWire — InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities, today announces...
VBI Vaccines Announces Dosing of First GBM Patient in Phase 1/2a Clinical Study of VBI-1901
17 janv. 2018 08h00 HE
|
VBI Vaccines, Inc.
Two-part Phase 1/2a study of VBI-1901 to enroll patients with recurrent GBM Part A: Dose escalation to enroll up to 18 patientsPart B: Subsequent extension of optimal dose to enroll up to 10...
VBI Vaccines to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference
12 déc. 2017 08h00 HE
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Dec. 12, 2017 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) (TSX:VBV) (VBI) today announced that Jeff Baxter, President and CEO, will present at the BMO Capital Markets...